Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

Publisher： John Wiley & Sons Inc

E-ISSN： 2326-5205|67|3|668-677

ISSN： 2326-5191

Source： ARTHRITIS & RHEUMATOLOGY, Vol.67, Iss.3, 2015-03, pp. : 668-677

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 2151-464X, Iss. 10, 2015-10 ,pp. : 1475-1480

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 10, 2015-10 ,pp. : 1475-1480

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24‐Week Patient‐Reported Outcome Results of a Phase III, Multicenter Study

By  

ARTHRITIS CARE AND RESEARCH, Vol. 66, Iss. 7, 2014-07 ,pp. : 1085-1092

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 12, 2015-12 ,pp. : 3104-3112

John Wiley & Sons Inc

Access to resources Recommend Favorite

Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 9, 2015-09 ,pp. : 2369-2375

John Wiley & Sons Inc

Access to resources Recommend Favorite